Antonia Resag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonia Resag has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Marc Schmitz
Institute of Immunology, Faculty of Medicine Carl Gustav Carus TUD Dresden University of Technology Dresden Germany
2 shared publications - Patrizia Stoitzner
Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria
2 shared publications - Andrej Ozaniak
Charles Univ Prague, Fac Med 1, Dept Surg 3, V Uvalu 84, Prague 5, Czech Republic
1 shared publication - Antonio Rosato
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
1 shared publication Barbara Del Frari
Department of Plastic, Reconstructive and Aesthetic Surgery Medical University Innsbruck Innsbruck Austria
1 shared publication- Barbara Del Frari
Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University Innsbruck, Innsbruck, Austria
1 shared publication
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (6)
Granzyme B + T Cell Infiltration Distinguishes Cutaneous Squamous Cell Carcinoma From Actinic Keratosis
- 16 November 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (6)
Open AccessGranzyme B + T Cell Infiltration Distinguishes Cutaneous Squamous Cell Carcinoma From Actinic Keratosis
- Open Access
Targeting Langerhans cells using a modular mannosylated nucleic acid-based vaccine platform
The skin is a diverse reservoir of immune cells with strong potential for immunotherapeutic delivery. Langerhans cells (LCs) in the epidermis are antigen-presenting cells, accessible for vaccination using carbohydrate-conjugated therapeutics targeting their endocytic lectin receptor, Langerin. As carbohydrate-lectin binding is highly dependent on valency, scaffolds that enable control over ligand spacing and stoichiometry are instrumental in enhancing receptor binding and selectivity. Here we utilized a self-assembled nucleic acid-based Holliday Junction scaffold, fully modified for nuclease protection and with a well-defined carbohydrate arrangement to optimize drug delivery to LCs. In vitro screening with Langerin-expressing cells revealed that mannosylated Holliday Junctions showed the strongest binding. This was confirmed in human epidermal cell suspensions, demonstrating specificity and valency-driven interactions. Topical administration of mannosylated scaffolds on skin explants enabled effective targeting of epidermal LCs. Finally, in an antigen-presentation assay, in vitro differentiated LCs loaded with mannosylated and peptide-conjugated scaffolds significantly enhanced T cell activation. Overall, our study presents a promising nucleic acid-based platform for precise LC targeting and drug delivery, with broad potential for skin-directed immunotherapies.
Open AccessTargeting Langerhans cells using a modular mannosylated nucleic acid-based vaccine platform
The skin is a diverse reservoir of immune cells with strong potential for immunotherapeutic delivery. Langerhans cells (LCs) in the epidermis are antigen-presenting cells, accessible for vaccination using carbohydrate-conjugated therapeutics targeting their endocytic lectin receptor, Langerin. As carbohydrate-lectin binding is highly dependent on valency, scaffolds that enable control over ligand spacing and stoichiometry are instrumental in enhancing receptor binding and selectivity. Here we utilized a self-assembled nucleic acid-based Holliday Junction scaffold, fully modified for nuclease protection and with a well-defined carbohydrate arrangement to optimize drug delivery to LCs. In vitro screening with Langerin-expressing cells revealed that mannosylated Holliday Junctions showed the strongest binding. This was confirmed in human epidermal cell suspensions, demonstrating specificity and valency-driven interactions. Topical administration of mannosylated scaffolds on skin explants enabled effective targeting of epidermal LCs. Finally, in an antigen-presentation assay, in vitro differentiated LCs loaded with mannosylated and peptide-conjugated scaffolds significantly enhanced T cell activation. Overall, our study presents a promising nucleic acid-based platform for precise LC targeting and drug delivery, with broad potential for skin-directed immunotherapies.
- Open Access
The Immune Contexture of Liposarcoma and Its Clinical Implications
Liposarcomas (LPS) are the most frequent malignancies in the soft tissue sarcoma family and consist of five distinctive histological subtypes, termed well-differentiated LPS, dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), pleomorphic LPS, and myxoid pleomorphic LPS. They display variations in genetic alterations, clinical behavior, and prognostic course. While accumulating evidence implicates a crucial role of the tumor immune contexture in shaping the response to anticancer treatments, the immunological landscape of LPS is highly variable across different subtypes. Thus, DDLPS is characterized by a higher abundance of infiltrating T cells, yet the opposite was reported for MLPS. Interestingly, a recent study indicated that the frequency of pre-existing T cells in soft tissue sarcomas has a predictive value for immune checkpoint inhibitor (CPI) therapy. Additionally, B cells and tertiary lymphoid structures were identified as potential biomarkers for the clinical outcome of LPS patients and response to CPI therapy. Furthermore, it was demonstrated that macrophages, predominantly of M2 polarization, are frequently associated with poor prognosis. An improved understanding of the complex LPS immune contexture enables the design and refinement of novel immunotherapeutic approaches. Here, we summarize recent studies focusing on the clinicopathological, genetic, and immunological determinants of LPS.
Open AccessThe Immune Contexture of Liposarcoma and Its Clinical Implications
Liposarcomas (LPS) are the most frequent malignancies in the soft tissue sarcoma family and consist of five distinctive histological subtypes, termed well-differentiated LPS, dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), pleomorphic LPS, and myxoid pleomorphic LPS. They display variations in genetic alterations, clinical behavior, and prognostic course. While accumulating evidence implicates a crucial role of the tumor immune contexture in shaping the response to anticancer treatments, the immunological landscape of LPS is highly variable across different subtypes. Thus, DDLPS is characterized by a higher abundance of infiltrating T cells, yet the opposite was reported for MLPS. Interestingly, a recent study indicated that the frequency of pre-existing T cells in soft tissue sarcomas has a predictive value for immune checkpoint inhibitor (CPI) therapy. Additionally, B cells and tertiary lymphoid structures were identified as potential biomarkers for the clinical outcome of LPS patients and response to CPI therapy. Furthermore, it was demonstrated that macrophages, predominantly of M2 polarization, are frequently associated with poor prognosis. An improved understanding of the complex LPS immune contexture enables the design and refinement of novel immunotherapeutic approaches. Here, we summarize recent studies focusing on the clinicopathological, genetic, and immunological determinants of LPS.